<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27550">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748070</url>
  </required_header>
  <id_info>
    <org_study_id>33096</org_study_id>
    <nct_id>NCT02748070</nct_id>
  </id_info>
  <brief_title>Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP)</brief_title>
  <official_title>The Role of Perioperative Systemic Steroids in Patients With Chronic Rhinosinusitis Without Polyps (CRSsNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      While oral steroids have been shown to be effective in the management of patients with
      chronic rhinosinusitis with polyps, its role in treating chronic rhinosinusitis without
      polyps (CRSsNP) is ambiguous. Despite a lack of strong clinical evidence to suggest a
      benefit in this disease state, steroids are often prescribed as a component of
      post-operative care after sinus surgery for patients without polyps. Oral steroids carry
      with them significant adverse effects, and should be prescribed thoughtfully. The aims of
      this study are to determine if oral steroids in the peri-operative period improves patient
      outcomes in CRS without polyps.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sino-nasal Outcome Test (SNOT 22)</measure>
    <time_frame>Baseline, change from baseline 1 week after surgery, change from baseline 4-6 weeks after surgery, change from baseline 8-12 weeks after surgery , change from baseline 6 months after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lund-Kennedy score</measure>
    <time_frame>Baseline, change from baseline 1 week after surgery, change from baseline 4-6 weeks after surgery, change from baseline 8-12 weeks after surgery , change from baseline 6 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid Side Effect Questionnaire</measure>
    <time_frame>Baseline 1 week after surgery, change from baseline 4-6 weeks after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <condition>Endoscopic Sinus Surgery</condition>
  <condition>Chronic Rhinosinusitis Without Polyps</condition>
  <condition>Oral Steroids</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Provided oral steroid and topical steroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Provided oral placebo and topical steroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flonase</intervention_name>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CRSsNP as defined by Clinical Practice Guideline (Update) on Adult Sinusitis

          -  scheduled to undergo endoscopic sinus surgery

        Exclusion Criteria:

          -  chronic rhinosinusitis with polyps (CRSwNP)

          -  Aspirin exacerbated respiratory disease

          -  Cystic fibrosis

          -  Immunosuppressive states (Human immunodeficiency virus, transplant)

          -  Oral steroid use within 30 days of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter H Hwang, M.D.</last_name>
    <phone>650-725-6500</phone>
    <email>phwang@ohns.stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia E Noel, M.D.</last_name>
    <phone>650-725-6500</phone>
    <email>jtomlin2@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter H Hwang, M.D.</last_name>
      <phone>650-725-6500</phone>
      <email>phwang@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julia E Noel, M.D.</last_name>
      <phone>650-725-6500</phone>
      <email>jtomlin2@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 19, 2016</lastchanged_date>
  <firstreceived_date>April 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Peter Haichin Hwang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
